CHAPEL HILL, N.C., April 3, 2015 /PRNewswire/ -- Part of the allure of Big Data for the pharmaceutical industry is how it can be used to inform key issues for different functions.
Medical records, clinical trial data and claims information are some of the information sources that pharma can use to produce Big Data insights that are useful to not only medical but also commercial and HEOR functions.
Pharma recognizes the huge potential that Big Data holds for providing unique insights into areas such as clinical development programs, new product pricing and clinical effectiveness - areas of keen interest to medical, commercial and HEOR functions, respectively.
To open a window into how these three functions view and utilize Big Data, research and consulting leader Best Practices, LLC has published a study that probes current trends and best practices in medical, commercial and HEOR functions utilizing Big Data.
The study, "Big Data in Pharma: Current & Future Trends for Big Data Utilization Across Medical, Commercial and HEOR Functions," addresses many issues that leaders across these three functions are wrestling with, including which functions are using and leading Big Data projects? The commercial segment is a high user of Big Data but HEOR is seen as the most likely leader of Big Data initiatives, according to commercial segment.
The data in this study provides an opportunity for gaining actionable insights that goes beyond what's currently available via white papers or symposiums. The depth of insights extends across the critical components of pharma-oriented Big Data programs and includes Medical, Commercial and HEOR perspectives on:
- The types of Big Data projects and data being used
- The types of data being used for specific medical Big Data projects
- The data types and sources that are most valuable
- How companies are organizing their Big Data efforts
- Who are the most useful partners for Big Data projects
Best Practices, LLC, conducted this customized study – with responses segmented by medical, commercial and HEOR functions – to better understand the growing influence of Big Data in the biopharmaceutical sector and how it impacts medical, HEOR, and commercial operations in the U.S.
To learn more about this report, download a complimentary report excerpt at http://www3.best-in-class.com/rr1345.htm.
For related research, visit our Best Practices, LLC website at www.best-in-class.com/.
ABOUT BEST PRACTICES, LLC
Best Practices, LLC is a leading benchmarking and advisory services firm serving pharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and most of the top 50 pharmaceutical companies. The firm conducts primary research and uses its comprehensive benchmarking tools and executives interviews to form the basis for our Benchmarking Reports and advisory services utilized by top executives. Best Practices, LLC believes in the profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies.
SOURCE Best Practices, LLC